Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine in Rituximab Refractory B-cell Indolent Lymphoma
NCT01570049Phase 3Unknown
- Sponsor
- Shandong Lanjin Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bendamustine in indolent B-cell non-Hodgkin lymphoma (iNHL), sponsored by Shandong Lanjin Pharmaceuticals. Status: unknown.
02
Drugs
bendamustine
03
Conditions
indolent B-cell non-Hodgkin lymphoma (iNHL)
Beyond the preview
Go deeper on NCT01570049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570049.